5-(2-Aminopropyl)indole (5-IT): A psychoactive substance used for recreational purposes is an inhibitor of human monoamine oxidase (MAO)

Drug Testing and Analysis

Volumn 6, Issue 7-8, 2014, Pages 607-613

  Herraiz, Tomás ^a   Brandt, Simon D ^b  

^a INSTITUTE OF FOOD SCIENCE   (Spain)

^b LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

Author keywords

5 IT; Harmaline; Indoles; Internet; MAO inhibitors; Monoamine oxidase; New Psychoactive Substances; Serotonin toxicity

Indexed keywords

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; POLYCYCLIC AROMATIC HYDROCARBONS;

5-IT; AMINOPROPYL; HARMALINE; IN-VITRO; INDOLE; MONOAMINE OXIDASE; MONOAMINE OXIDASE A; MONOAMINE OXIDASE INHIBITORS; NEW PSYCHOACTIVE SUBSTANCE; SEROTONIN TOXICITY;

TOXICITY;

5 (2 AMINOPROPYL)INDOLE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; ANTIDEPRESSANT AGENT; CLORGYLINE; HARMALINE; ILLICIT DRUG; INDOLE DERIVATIVE; KYNURAMINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEW DRUG; PSYCHOTROPIC AGENT; RECREATIONAL DRUG; SEROTONIN; TOLOXATONE; UNCLASSIFIED DRUG; 5-(2-AMINOPROPYL)INDOLE; AMINE OXIDASE (FLAVIN CONTAINING); MONOAMINE OXIDASE A, HUMAN;

ARTICLE; DRUG ABUSE; DRUG POTENCY; DRUG STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; ENZYME INHIBITION; HUMAN; INTOXICATION; MICHAELIS MENTEN KINETICS; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM;

HUMANS; INDOLES; KYNURAMINE; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; PSYCHOTROPIC DRUGS; SEROTONIN;

EID: 84904569991     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.1530     Document Type: Article

References (37)

1. EMCDDA. Risk assessment report of a new psychoactive substance: 5-(2-aminopropyl)indole. In accordance with article 6 of Council decision 2005/387/JHA on information exchange, risk assessment and control of new psychoactive substances, EMCDDA, Lisbon. Available at: http://register.consilium.europa.eu/pdf/en/13/st08/st08693.en13.pdf [1 July 2013].
2. Council decision 2005/387/JHA of 20 May 2005 on the information exchange, risk-assessment and control of new psychoactive substances. Official J. Eur. 2005, L 127/32.
3. International day against drug abuse & illicit trafficking: European Commission calls for EU wide ban on synthetic '5-IT' drug. Reference: IP/13/604. Available at: http://europa.eu/rapid/press-release_IP-13-604_en.htm?locale=en [28 July 2013].
4. A. Shulgin, A. Shulgin . Tihkal: The Continuation, Transform Press, Berkeley, CA, USA, 1997.
5. A. Hofmann, F. Troxler . Nouveaux dérivés de l'indole et leur préparation. French Patent No. 1344579, 1963.
6. F. Troxler, A. Harnisch, G. Bormann, F. Seemann, L. Szabo . Synthesen von Indolen mit (2-Aminoäthyl)-, (2-Aminopropyl)-oder Alkanolamin-Seitenketten am Sechsring. 5. Mitt. über synthetische Indol-Verbindungen. Helv. Chim. Acta 1968, 51, 1616.
7. A. Cerletti, M. Taeschler, H. Weidmann . Pharmacologic studies on the structure-activity relationship of hydroxyindole alkylamines. Adv. Pharmacol. 1968, 6, 233.
8. E.W. Boyer, M. Shannon . The serotonin syndrome. New Engl. J. Med. 2005, 352, 1112.
9. R. Kronstrand, M. Roman, M. Dahlgren, G. Thelander, M. Wikström, H. Druid . A cluster of deaths involving 5-(2-aminopropyl)Indole (5-IT). J. Anal. Toxicol. 2013, in press, DOI: 10.1093/jat/bkt058
10. H.B. Murphree, E.H. Jenney, R.H. Dippy, C.C. Pfeiffer . Effects in normal man of α-methyltryptamine and α-ethyltryptamine. Clin. Pharmacol. Ther. 1961, 2, 722.
11. H.B. Murphree Jr, E.H. Jenney, C.C. Pfeiffer . Comparison of the effects of congeners of lysergic acid diethylamide and tryptophane in normal volunteers. Pharmacologist 1960, 2, 64.
12. L.E. Hollister, J.J. Prusmack, J.A. Paulsen, N. Rosenquist . Comparison of three psychotropic drugs (psilocybin, JB-329, and IT-290) in volunteer subjects. J. Nerv. Ment. Dis. 1960, 131, 428.
13. A.T. Shulgin, D.E. Nichols . Characterization of three new psychotomimetics, in The Psychopharmacology of Hallucinogens, (Eds: R.C. Stillman, R.E. Willette ), Pergamon, New York, 1978, pp. 74.
14. J. Wilcox . Psychoactive properties of alpha-methyltryptamine: Analysis from self reports of users. J. Psychoactive Drugs 2012, 44, 274.
15. K.R. Scott, J.D. Power, S.D. McDermott, et al. Identification of (2-aminopropyl)indole positional isomers in forensic samples. Drug Test. Anal. 2013, DOI: 10.1002/dta.1508
16. T. Herraiz, C. Chaparro . Analysis of monoamine oxidase enzymatic activity by reversed-phase high performance liquid chromatography and inhibition by beta-carboline alkaloids occurring in foods and plants. J. Chromatogr. A 2006, 1120, 237.
17. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099.
18. S.P. Elliott, S.D. Brandt, S. Freeman, R.P. Archer . AMT (3-(2-aminopropyl)indole) and 5-IT (5-(2-aminopropyl)indole): An analytical challenge and implications for forensic analysis. Drug Test. Anal. 2013, 5, 196.
19. T. Herraiz, D. González, C. Ancín-Azpilicueta, V.J. Arán, H. Guillén . β-Carboline alkaloids in Peganum harmala and inhibition of human monoamine oxidase (MAO). Food Chem. Toxicol. 2010, 48, 839.
20. I. Berlin, R. Zimmer, H.M. Thiede, et al. Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects. Brit. J. Clin. Pharmacol. 1990, 30, 805.
21. R. Kettler, M. Da Prada, W.P. Burkard . Comparison of monoamine oxidase-A inhibition by moclobemide in vitro and ex vivo in rats. Acta Psychiatr. Scand. Suppl. 1990, 360, 101.
22. J. Fritze, G. Laux, E. Sofic, et al. Plasma moclobemide and metabolites: Lack of correlation with clinical response and biogenic amines. Psychopharmacology (Berl) 1989, 99, 252.
23. M.S. Benedetti, T. Boucher, C.J. Fowler . The deamination of noradrenaline and 5-hydroxytryptamine by rat brain and heart monoamine oxidase and their inhibition by cimoxatone, toloxatone and MD 770222. Naunyn-Schmiedeberg's Arch. Pharmacol. 1983, 323, 315.
24. C.L. Zirkle, C. Kaiser, Monoamine oxidase inhibitors (nonhydrazine), in Psychopharmacological Agents, Volume 1, (Ed: M. Gordon ), Academic Press, New York, 1964, pp. 445.
25. A.W. Lessin, R.F. Long, M.W. Parkes . Central stimulant actions of α-alkyl substituted tryptamines in mice. Brit. J. Pharmacol. Chemother. 1965, 24, 49.
26. G.M. Maxwell . The effects of an indole derivative 6-(2'-aminopropyl indole) on the general and coronary haemodynamics of the intact dog. Experientia 1964, 20, 526.
27. H. Sternbach . The serotonin syndrome. Am. J. Psychiatry 1991, 148, 705.
28. J.L. Pilgrim, D. Gerostamoulos, N. Woodford, O.H. Drummer . Serotonin toxicity involving MDMA (ecstasy) and moclobemide. Forensic Sci. Int. 2012, 215, 184.
29. P.K. Gillman . Ecstasy, serotonin syndrome and the treatment of hyperpyrexia. Med. J. Aust. 1997, 167, 109.
30. C. Sun-Edelstein, S.J. Tepper, R.E. Shapiro . Drug-induced serotonin syndrome: A review. Expert Opin. Drug Saf. 2008, 7, 587.
31. J.C. Callaway, C.S. Grob . Ayahuasca preparations and serotonin reuptake inhibitors: A potential combination for severe adverse interactions. J. Psychoactive Drugs 1998, 30, 367.
32. P.H. Yu, A.A. Boulton . Irreversible inhibition of monoamine oxidase by some components of cigarette smoke. Life Sci. 1987, 41, 675.
33. T. Herraiz, C. Chaparro . Human monoamine oxidase is inhibited by tobacco smoke: β-carboline alkaloids act as potent and reversible inhibitors. Biochem. Biophys. Res. Commun. 2005, 326, 378.
34. J.S. Fowler, N.D. Volkow, G.J. Wang, et al. Brain monoamine oxidase A inhibition in cigarette smokers. Proc. Natl. Acad. Sci. USA 1996, 93, 14065.
35. A. Shulgin, A. Shulgin . PIHKAL. A Chemical Love Story, Transform Press, Berkeley, USA, 1991.
36. A.T. Shulgin, T. Manning, P.F. Daley . The Shulgin Index. Volume 1. Psychedelic phenethylamines and related compounds, Transform Press, Berkeley, CA, USA, 2011.
37. D. Trachsel, D. Lehmann, C. Enzensperger . Phenethylamine: Von der Struktur zur Funktion, Nachtschatten Verlag, Solothurn, 2013.